HealthFDA places clinical hold on Regenxbio’s Hunter syndrome gene therapy
Regenxbio said the U.S. FDA placed its experimental gene therapy for a rare inherited disorder on clinical hold after spinal scans showed abnormalities in five participants. Its shares fell more than 24% in premarket trading.
R
Reuters★★★☆☆2026-08-24 14:50Original
FDA places clinical hold on Regenxbio’s Hunter syndrome gene therapy
Health